Француска - Француски - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - quinapril base 20 mg sous forme de : chlorhydrate de quinapril 21; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > quinapril base 20 mg sous forme de : chlorhydrate de quinapril 21,66 mg > hydrochlorothiazide 12,5 mg - quinapril et diurétiques - classe pharmacothérapeutique : quinapril et diurétiques - code atc : c09ba06.les comprimés pelliculés de quinapril/hydrochlorothiazide arrow lab contiennent deux substances actives qui s'appellent (i) le quinapril et (ii) l'hydrochlorothiazide. ces deux substances actives diminuent la tension artérielle.(i) le quinapril appartient à un groupe de médicaments connus sous le nom d’ « inhibiteurs de l'enzyme de conversion de l'angiotensine (iec) ». le quinapril aide les vaisseaux sanguins à se relaxer, en abaissant ainsi la tension artérielle.(ii) l'hydrochlorothiazide appartient à un groupe de médicaments appelés « diurétiques thiazidiques » (qu'on appelle aussi des « diurétiques »). l'hydrochlorothiazide inhibe la capacité des reins à retenir les fluides, ce qui entraîne une diminution de la tension artérielle.quinapril/hydrochlorothiazide arrow lab est utilisé pour traiter une tension artérielle élevée chez des patients qui prennent déjà (i) du quinapril et (ii) de l'hydrochlorothiazide sous forme de comprimés séparés, et qui pourraient tirer un bénéfice de la prise d'un seul comprimé contenant les deux substances.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 20 mg - quinapril hydrochloride/hydrochlorothiazide tablets are indicated for the treatment of hypertension.  this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration ). in using quinapril hydrochloride/hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that quinapril does not have a similar risk (see warnings: neutropenia/agranulocytosis ). angioedema in black patients black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials, ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril hydrochloride/hydrochlorothiazidetablets are contraindicated

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

bluepoint laboratories - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 5 mg - quinapril tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and t

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 5 mg - quinapril tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. quinapril tablets usp may be used alone or in combination with thiazide diuretics. heart failure quinapril tablets usp is indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. in using quinapril tablets usp, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to show that quinapril tablets usp does not have a similar risk (see warnings). black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ace inhibitor. quinapril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer quinapril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings and precautions). do not co-administer quinapril with aliskiren in patients with diabetes.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

american health packaging - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 20 mg - quinapril tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and t

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

rebel distributors corp - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811) - quinapril 5 mg - quinapril tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using quinapril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to show that quinapril tablets does not have a similar risk (see warnings ). black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ace inhibitor.

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. - quinaprilhydrochloride 0-water samenstelling overeenkomend met ; ; quinapril - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; crospovidon (e 1202) ; gelatine (e 441) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; magnesiumsubcarbonaat (e 504 ii) ; polyethyleenglycol (e 1521) ; titaandioxide (e 171), - quinapril

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. - quinaprilhydrochloride 0-water samenstelling overeenkomend met ; ; quinapril - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; crospovidon (e 1202) ; gelatine (e 441) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; magnesiumsubcarbonaat (e 504 ii) ; polyethyleenglycol (e 1521) ; titaandioxide (e 171), - quinapril

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. - quinaprilhydrochloride 0-water samenstelling overeenkomend met ; ; quinapril - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; crospovidon (e 1202) ; gelatine (e 441) ; hypromellose (e 464) ; ijzeroxide geel (e 172) ; magnesiumstearaat (e 470b) ; magnesiumsubcarbonaat (e 504 ii) ; polyethyleenglycol (e 1521) ; titaandioxide (e 171), - quinapril

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. - quinaprilhydrochloride 0-water samenstelling overeenkomend met ; ; quinapril - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; crospovidon (e 1202) ; gelatine (e 441) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; magnesiumsubcarbonaat (e 504 ii) ; polyethyleenglycol (e 1521) ; titaandioxide (e 171), - quinapril